Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
2006 1
2007 1
2008 6
2009 11
2010 11
2011 8
2012 6
2013 10
2014 6
2015 6
2016 7
2017 12
2018 9
2019 8
2020 9
2021 11
2022 10
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
Corpechot C, Carrat F, Gaouar F, Chau F, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Schramm C, Pares A, Olivas I, Eaton JE, Osman KT, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Dumortier J, Bruns T, Große K, Pageaux GP, Wetten A, Dyson J, Jones D, Chazouillères O, Hansen B, de Lédinghen V; Global & ERN Rare-Liver PBC Study Groups. Corpechot C, et al. Among authors: calvaruso v. J Hepatol. 2022 Dec;77(6):1545-1553. doi: 10.1016/j.jhep.2022.06.017. Epub 2022 Jun 28. J Hepatol. 2022. PMID: 35777587 Free article.
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Corpechot C, Lemoinne S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Pares A, Olivas I, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Dumortier J, Pageaux GP, de Lédinghen V, Chazouillères O, Carrat F; Global & ERN Rare-Liver PBC Study Groups. Corpechot C, et al. Among authors: calvaruso v. Hepatology. 2024 Jan 1;79(1):39-48. doi: 10.1097/HEP.0000000000000529. Epub 2023 Jul 3. Hepatology. 2024. PMID: 37399238
Hepatic benefits of HCV cure.
Calvaruso V, Craxì A. Calvaruso V, et al. J Hepatol. 2020 Dec;73(6):1548-1556. doi: 10.1016/j.jhep.2020.08.006. Epub 2020 Aug 7. J Hepatol. 2020. PMID: 32777323 Review.
Is global elimination of HCV realistic?
Calvaruso V, Petta S, Craxì A. Calvaruso V, et al. Liver Int. 2018 Feb;38 Suppl 1:40-46. doi: 10.1111/liv.13668. Liver Int. 2018. PMID: 29427499 Review.
Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein.
Bianchini F, Crivelli V, Abernathy ME, Guerra C, Palus M, Muri J, Marcotte H, Piralla A, Pedotti M, De Gasparo R, Simonelli L, Matkovic M, Toscano C, Biggiogero M, Calvaruso V, Svoboda P, Cervantes Rincón T, Fava T, Podešvová L, Shanbhag AA, Celoria A, Sgrignani J, Stefanik M, Hönig V, Pranclova V, Michalcikova T, Prochazka J, Guerrini G, Mehn D, Ciabattini A, Abolhassani H, Jarrossay D, Uguccioni M, Medaglini D, Pan-Hammarström Q, Calzolai L, Fernandez D, Baldanti F, Franzetti-Pellanda A, Garzoni C, Sedlacek R, Ruzek D, Varani L, Cavalli A, Barnes CO, Robbiani DF. Bianchini F, et al. Among authors: calvaruso v. Sci Immunol. 2023 Mar 17;8(81):eade0958. doi: 10.1126/sciimmunol.ade0958. Epub 2023 Mar 10. Sci Immunol. 2023. PMID: 36701425 Free PMC article.
Real life experiences in HCV management in 2018.
Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL. Viganò M, et al. Among authors: calvaruso v. Expert Rev Anti Infect Ther. 2019 Feb;17(2):117-128. doi: 10.1080/14787210.2019.1563755. Epub 2019 Jan 15. Expert Rev Anti Infect Ther. 2019. PMID: 30582384 Free article. Review.
Immunological alterations in hepatitis C virus infection.
Calvaruso V, Craxì A. Calvaruso V, et al. World J Gastroenterol. 2013 Dec 21;19(47):8916-23. doi: 10.3748/wjg.v19.i47.8916. World J Gastroenterol. 2013. PMID: 24379616 Free PMC article. Review.
Clinical implications of the hyperdynamic syndrome in cirrhosis.
Licata A, Mazzola A, Ingrassia D, Calvaruso V, Cammà C, Craxì A. Licata A, et al. Among authors: calvaruso v. Eur J Intern Med. 2014 Nov;25(9):795-802. doi: 10.1016/j.ejim.2014.09.004. Epub 2014 Sep 20. Eur J Intern Med. 2014. PMID: 25245607 Review.
118 results